CETP gene variation: Relation to lipid parameters and cardiovascular risk

Current Opinion in Lipidology

Volumn 15, Issue 4, 2004, Pages 393-398

  Boekholdt, S Matthijs ^a   Kuivenhoven, Jan Albert ^a   Hovingh, G Kees ^a   Jukema, J Wouter ^b   Kastelein, John J P ^a   Van Tol, Arie ^c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

CETP; Cholesteryl ester transfer protein; Coronary artery disease; Genetics; HDL

Indexed keywords

AMINO ACID; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN; PRAVASTATIN;

AMINO ACID SUBSTITUTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTERYL ESTER TRANSFER PROTEIN GENE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SCREENING; GENE; GENE ACTIVITY; GENE INTERACTION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; INSTRUMENT; LIPOPROTEIN BLOOD LEVEL; META ANALYSIS; PARAMETER; PARTICLE SIZE; POPULATION RESEARCH; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT;

CARDIOVASCULAR DISEASES; CARRIER PROTEINS; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CORONARY VESSELS; GENOTYPE; GLYCOPROTEINS; HUMANS; LIPID METABOLISM; LIPOPROTEINS, HDL; MUTATION; PRAVASTATIN; VARIATION (GENETICS);

EID: 4043096347     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mol.0000137226.54278.60     Document Type: Review

References (77)

1. Scandinavian Simvastatin Survival Study investigators. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
2. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with Simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
3. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-1307.
4. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62:707-714.
5. Miller NE, Thelle DS, Forde OH, et al. The Tromso heart-study. High-density lipoprotein and coronary heart-disease: a prospective cass-control study. Lancet 1977; 1:965-968.
6. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-1847.
7. Gotto AM Jr. Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report. Circulation 2001; 103:2213-2218.
8. De Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II doss-response study. Circulation 2002; 105:2159-2165.
9. Clark RW, Sutfin TA, Ruggeri RB, et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 2004; 24:490-497.
10. Marotti KR, Castle CK, Boyle TP, et al. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 1993; 364:73-75.
11. Plump AS, Masucci-Magoulas L, Bruce C, et al. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol 1999; 19:1105-1110.
12. Hayek T, Masucci-Magoulas L, Jiang X, et al. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest 1995; 96:2071-2074.
13. Arai T, Yamashita S, Sakai N, et al. A novel nonsense mutation (G181X) in the human cholesteryl ester transfer protein gene in Japanese hyperalphalipoproteinemic subjects. J Lipid Res 1996; 37:2145-2150.
14. Jap TS, Wu YC, Tso YC, et al. A novel mutation in the intron 1 splice donor site of the cholesterol ester transfer protein (CETP) gene as a cause of hyperalphalipoproteinemia. Metabolism 2002; 51:394-397.
15. Funke H, Wiebusch H, Fuer L, et al. Identification of mutations in the cholesterol ester transfer protein in Europeans with elevated high density lipoprotein cholesterol. Circulation 1994; 90:1-124.
16. Ritsch A, Drexel H, Amann FW, et al. Deficiency of cholesteryl ester transfer protein. Description of the molecular defect and the dissociation of cholesteryl ester and triglyceride transport in plasma. Arterioscler Thromb Vasc Biol 1997; 17:3433-3441.
17. Teh EM, Dolphin PJ, Breckenridge WC, et al. Human plasma CETP deficiency: identification of a novel mutation in exon 9 of the CETP gene in a Caucasian subject from North America. J Lipid Res 1998; 39:442-456.
18. Ramsbottom D, O'Neill A, Sexton DM, et al. The cholesteryl ester transfer protein (CETP) locus as a candidate gene in abdominal aortic aneurysm. Clin Genet 1997; 51:241-245.
19. Gotoda T, Kinoshita M, Shimano H, et al. Cholesteryl ester transfer protein deficiency caused by a nonsense mutation detected in the patient's macrophage mRNA. Biochem Biophys Res Commun 1993; 194:519-524.
20. Sakai N, Santamarina-Fojo S, Yamashita S, et al. Exon 10 skipping caused by intron 10 splice donor site mutation in cholesteryl ester transfer protein gene results in abnormal downstream splice site selection. J Lipid Res 1996; 37:2065-2073.
21. Brown ML, Inazu A, Hesler CB, et al. Molecular basis of lipid transfer deficiency in a family with increased high-density lipoproteins. Nature 1989; 342:448-451.
22. Inazu A, Jiang XC, Haraki T, et al. Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol. J Clin Invest 1994; 94:1872-1882.
23. Boekholdt SM, Thompson JF. Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. J Lipid Res 2003; 44:1080-1093. This meta-analysis provides large-scale evidence that both the Taq1B and I405V variants are significantly associated with CETP activity and HDL-c levels.
24. Koizumi J, Mabuchi H, Yoshimura A, et al. Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia. Atherosclerosis 1985; 58:175-186.
25. Yamashita S, Matsuzawa Y, Okazaki M, et al. Small polydisperse low density lipoproteins in familial hyperalphalipoproteinemia with complete deficiency of cholesteryl ester transfer activity. Atherosclerosis 1988; 70:7-12.
26. Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl-ester transfer protein gene despite increased HDL levels. J Clin Invest 1996; 97:2917-2923.
27. Inazu AM, Brown ML, Hesler CB, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990; 323:1234-1238.
28. Akita H, Chiba H, Tschuchihashi K, et al. Cholesteryl ester transfer protein gene: two common mutations and their effect on plasma high-density lipoprotein cholesterol content. J Clin Endocrinol Metab 1994; 79:1615-1618.
29. Arai T, Tsukada T, Murase T, et al. Particle size analysis of high density lipoproteins in patients with genetic cholesteryl ester transfer protein deficiency. Clin Chim Acta 2000; 301:103-117.
30. Chiba H, Akita H, Tsuchihashi K, et al. Quantitative and compositional changes in high density lipoprotein subclasses in patients with various genotypes of cholesteryl ester transfer protein deficiency. J Lipid Res 1997; 38:1204-1216.
31. Nagano M, Yamashita S, Hirano K, et al. Point mutation (-69 G→A) in the promoter region of cholesteryl ester transfer protein gene in Japanese hyperalphalipoproteinemic subjects. Arterioscler Thromb Vasc Biol 2001; 21:985-990.
32. Inazu A, Nishimura Y, Tereda Y, et al. Effects of hepatic lipase gene promoter nucleotide variations on serum HDL cholesterol concentration in the general Japanese population. J Hum Genet 2001; 46:172-177.
33. Maruyama T, Sakai N, Ishigami M, et al. Prevalence and phenotypic spectrum of cholesteryl ester transfer protein gene mutations in Japanese hyperalphalipoproteinemia. Atherosclerosis 2003; 166:177-185.
34. Ma YQ, Thomas GN, Critchley JA, et al. Identification of the intron 14 splicing defect of the cholesteryl ester transfer protein gene in Hong Kong Chinese. Clin Genet 2001; 59:287-289.
35. Arashiro R, Katsuren K, Maung K, et al. Effect of a common mutation (D442G) of the cholesteryl ester transfer protein gene on lipids and lipoproteins in children. Pediatr Res 2001; 50:455-459.
36. Kimura H, Gejyo F, Suzuki S, et al. A common mutation of cholesteryl ester transfer protein gene in dialysis patients. Kidney Int 1999; 56:S186-S189.
37. Sakai N, Yamashita S, Hirano KI, et al. Frequency of exon 15 missense mutation (442D:G) in cholesteryl transfer protein gene in hyperalphalipoproteinemic Japanese subjects. Atherosclerosis 1995; 114:139-145.
38. Hirano K, Yamashita S, Nakajima N, et al. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol 1997; 17:1053-1059.
39. Inazu A, Brown ML, Hesler CB, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990; 323:1234-1238.
40. Moriyama Y, Okamura T, Inazu A, et al. A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev Med 1998; 27:659-667.
41. Wu JH, Lee YT, Hsu HC, et al. Influence of CETP gene variation on plasma lipid levels and coronary heart disease: a survey in Taiwan. Atherosclerosis 2001; 159:451-458.
42. Wang JH, Qiang H, Chen D, et al. CETP gene mutation (D442G) increases low-density lipoprotein particle size in patients with coronary heart disease. Clin Chim Acta 2002; 322:85-90.
43. Barter PJ, Brewer HB Jr, Chapman MJ, et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23:160-167.
44. Klerkx AH, Hovingh GK, Nooteboom I, et al. A novel intronic CETP mutation (In7+1) in Dutch subjects with hyperalphalipoproteinemia. Circulation 2003; 108 (Suppl):997.
45. Nagano M, Yamashita S, Hirano K, et al. Two novel missense mutations in the CETP gene in Japanese hyperalphaproteinemic subjects: high throughput assay by Invader assay. J Lipid Res 2002; 43:1011-1018.
46. Cargill M, Altshuler J, Ireland J, et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet 1999; 22:231-238.
47. Freeman DJ, Shepherd J, Packard CJ, et al. An Stul RFLP at the human cholesteryl ester transfer protein (CETP) locus. Nucleic Acids Res 1989; 17:2880.
48. Agellon LB, Quinet EM, Gillette TG, et al. Organization of the human cholesteryl ester transfer protein gene. Biochemistry 1990; 29:1372-1376.
49. Takahashi K, Jiang XC, Sakai N, et al. A missense mutation in the cholesteryl ester transfer protein gene with possible dominant effects on plasma high density lipoproteins. J Clin Invest 1993; 92:2060-2064.
50. Corbex M, Poirier O, Fumeron F, et al. Extensive association analysis between the CETP gene and coronary heart disease phenotypes reveals several putative functional polymorphisms and gene-environment interaction. Genet Epidemiol 2000; 19:64-80.
51. Kakko S, Tamminen M, Paivansalo M, et al. Variation at the cholesteryl ester transfer protein gene in relation to plasma high density lipoproteins cholesterol levels and carotid intima-media thickness. Eur J Clin Invest 2001; 31:593-602.
52. Thompson JF, Lira ME, Durham LK, et al. Polymorphisms in the CETP gene and association with CETP mass and HDL levels. Atherosclerosis 2003; 167:195-204.
53. Friedlander Y, Leitersdorf E, Vecsler R, et al. The contribution of candidate genes to the response of plasma lipids and lipoproteins to dietary challenge. Atherosclerosis 2000; 152:239-248.
54. Pallaud C, Gueguen R, Sass C, et al. Genetic influences on the lipid metabolism trait variability within the Stanislas cohort. J Lipid Res 2001; 42:1879-1890.
55. Slominsky PA, Metelskaya VA, Miloserdova OV, et al. Analysis of the possible role of genetic factors in determination of the concentration of high-density-lipoprotein cholesterol in the Moscow population. Russ J Genet 2000; 36:1177-1180.
56. Gudnason V, Kakko S, Nicaud V, et al. Cholesteryl ester transfer protein gene effect on CETP activity and plasma high-density lipoprotein in European populations. Eur J Clin Invest 1999; 29:116-128.
57. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, et al. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein. Circulation 2000; 101:1907-1912.
58. Bruce C, Sharp DS, Tall AR. Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia. J Lipid Res 1998; 39:1071-1078.
59. Barzilai N, Atzmon G, Schechter C, et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA 2003; 290:2030-2040. Interesting study investigating determinants of longevity. The I405V variant has been previously related with lipoprotein levels, lipoprotein size, and CAD risk. This study confirms the relationship with lipoprotein size and, in addition, relates it to longevity.
60. Ordovas JM, Cupples A, Corella D, et al. Association of cholesteryl ester transfer protein-Taq1B polymorphism with variations in lipoprotein subclasses and coronary heart disease risk. The Framingham study. Arterioscler Thromb Vasc Biol 2000; 20:1323-1329.
61. De Grooth GJ, Smilde TJ, van Wissen S, et al. The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. Atherosclerosis 2004; 173:260-267.
62. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996; 276:875-881.
63. Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996; 276:882-888.
64. Kondo I, Berg K, Drayna D, et al. DNA polymorphism at the locus for human cholesteryl ester transfer protein (CETP) is associated with high density lipoprotein cholesterol and apolipoprotein levels. Clin Genet 1989; 35:49-56.
65. Klerkx AH, Tanck MW, Kastelein JJ, et al. Haplotype analysis of the CETP gene: not Taq1B, but the closely linked -629 C→A polymorphism and a novel promoter variant are independently associated with CETP concentration. Hum Mol Genet 2003; 12:111-123. This extensive haplotype analysis of the CETP promoter region confirms a previous study which suggested that the Taq1B variant is not instrumental in determining CETP or HDL-c levels, but a marker for the -629 promoter variant.
66. Eiriksdottir G, Bolla MK, Thorsson B, et al. The 629 > A polymorphism in the CETP gene does not explain the association of the Taq1B polymorphism with risk and age of Myocardial Infarction in Icelandic men. Atherosclerosis 2001; 159:187-192.
67. Dachet C, Poirier O, Cambien F, et al. New functional promoter polymorphism, CETP/-629, in cholesteryl ester transfer protein (CETP) gene related to CETP mass and high density lipoprotein cholesterol levels: role of Sp1/Sp3 in transcriptional regulation. Arterioscler Thromb Vasc Biol 2000; 20:507-515.
68. Kauma H, Savolainen M, Heikkila R, et al. Sex difference in the regulation of plasma high density lipoprotein cholesterol by genetic and environmental factors. Hum Genet 1996; 97:156-162.
69. Freeman DJ, Griffin BA, Holmes AP, et al. Regulation of plasma HDL cholesterol and subfraction distribution by genetic and environmental factors. Associations between the Taq1B RFLP in the CETP gene and smoking and obesity. Arterioscler Thromb 1994; 14:336-344.
70. Vohl MC, Lamarche B, Pascot A, et al. Contribution of the cholesteryl ester transfer protein gene Taq1B polymorphism to the reduced plasma HDL-cholesterol levels found in abdominal obese men with the features of the insulin resistance syndrome Int J Obes Relat Metab Disord 1999; 23:918-925.
71. Fumeron F, Betoulle D, Luc G, et al. Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction. J Clin Invest 1995; 96:1664-1671.
72. Blankenberg S, Rupprecht HJ, Bickel C, et al. Common genetic variation of the cholesteryl ester transfer protein gene strongly predicts future cardiovascular death in patients with coronary artery disease. J Am Coll Cardiol 2003; 41:1983-1989.
73. Kuivenhoven JA, Jukema JW, Zwinderman AH, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med 1998; 338:86-93.
74. Jukema JW, Bruschke AVG, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the regression growth evaluation statin study (REGRESS). Circulation 1995; 91:2528-2540.
75. Klerkx AH, De Grooth GJ, Zwinderman AH, et al. Cholesteryl ester transfer protein (CETP) concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS). Eur J Clin Invest 2003; 34:21-28.
76. Freeman DJ, Samani NJ, Wilson V, et al. A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study. Eur Heart J 2003; 24:1833-1842. Subanalysis of the West of Scotland coronary prevention study trial to investigate a potential clinically relevant pharmacogenetic interaction between the Taq1B variant and pravastatin therapy using the incidence of cardiovascular events as outcome.
77. De Grooth GJ, Zerba KE, Huang SP, et al. The cholesteryl ester transfer protein (CETP) Taq1B polymorphism in the Cholesterol And ecurrent Events study (CARE): no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome. J Am Coll Cardiol 2004; 43:854-857. Subanalysis of the cholesterol and recurrent events trial also investigating the potential clinically relevant pharmacogenetic interaction between the Taq1B variant and pravastatin therapy using the incidence of cardiovascular events as outcome.